These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 26214590)

  • 1. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.
    Krauthammer M; Kong Y; Bacchiocchi A; Evans P; Pornputtapong N; Wu C; McCusker JP; Ma S; Cheng E; Straub R; Serin M; Bosenberg M; Ariyan S; Narayan D; Sznol M; Kluger HM; Mane S; Schlessinger J; Lifton RP; Halaban R
    Nat Genet; 2015 Sep; 47(9):996-1002. PubMed ID: 26214590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
    Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
    Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NF1 gene in tumor syndromes and melanoma.
    Kiuru M; Busam KJ
    Lab Invest; 2017 Feb; 97(2):146-157. PubMed ID: 28067895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
    Nissan MH; Pratilas CA; Jones AM; Ramirez R; Won H; Liu C; Tiwari S; Kong L; Hanrahan AJ; Yao Z; Merghoub T; Ribas A; Chapman PB; Yaeger R; Taylor BS; Schultz N; Berger MF; Rosen N; Solit DB
    Cancer Res; 2014 Apr; 74(8):2340-50. PubMed ID: 24576830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.
    Cirenajwis H; Lauss M; Ekedahl H; Törngren T; Kvist A; Saal LH; Olsson H; Staaf J; Carneiro A; Ingvar C; Harbst K; Hayward NK; Jönsson G
    Mol Oncol; 2017 Apr; 11(4):438-451. PubMed ID: 28267273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
    Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
    Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
    Hintzsche JD; Gorden NT; Amato CM; Kim J; Wuensch KE; Robinson SE; Applegate AJ; Couts KL; Medina TM; Wells KR; Wisell JA; McCarter MD; Box NF; Shellman YG; Gonzalez RC; Lewis KD; Tentler JJ; Tan AC; Robinson WA
    Melanoma Res; 2017 Jun; 27(3):189-199. PubMed ID: 28296713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF1 mutations in conjunctival melanoma.
    Scholz SL; Cosgarea I; Süßkind D; Murali R; Möller I; Reis H; Leonardelli S; Schilling B; Schimming T; Hadaschik E; Franklin C; Paschen A; Sucker A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
    Br J Cancer; 2018 May; 118(9):1243-1247. PubMed ID: 29559732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF1 Mutations Prevalent but Not Clinically Relevant.
    Cancer Discov; 2015 Oct; 5(10):OF1. PubMed ID: 26283687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy.
    Demirci H; Demirci FY; Ciftci S; Elner VM; Wu YM; Ning Y; Chinnaiyan A; Robinson DR
    JAMA Ophthalmol; 2019 Dec; 137(12):1444-1448. PubMed ID: 31647501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver?
    Kadokura A; Frydenlund N; Leone DA; Yang S; Hoang MP; Deng A; Hernandez-Perez M; Biswas A; Singh R; Yaar R; Mahalingam M
    Hum Pathol; 2016 Jul; 53():82-90. PubMed ID: 26980030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
    Ming Z; Lim SY; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
    Krauthammer M; Kong Y; Ha BH; Evans P; Bacchiocchi A; McCusker JP; Cheng E; Davis MJ; Goh G; Choi M; Ariyan S; Narayan D; Dutton-Regester K; Capatana A; Holman EC; Bosenberg M; Sznol M; Kluger HM; Brash DE; Stern DF; Materin MA; Lo RS; Mane S; Ma S; Kidd KK; Hayward NK; Lifton RP; Schlessinger J; Boggon TJ; Halaban R
    Nat Genet; 2012 Sep; 44(9):1006-14. PubMed ID: 22842228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intragenic NF1 deletions in sinonasal mucosal malignant melanoma.
    Riobello C; Casanueva Muruais R; Suárez-Fernández L; García-Marín R; Cabal VN; Blanco-Lorenzo V; Franchi A; Laco J; López F; Llorente JL; Hermsen MA
    Pigment Cell Melanoma Res; 2022 Jan; 35(1):88-96. PubMed ID: 34547192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent inactivating RASA2 mutations in melanoma.
    Arafeh R; Qutob N; Emmanuel R; Keren-Paz A; Madore J; Elkahloun A; Wilmott JS; Gartner JJ; Di Pizio A; Winograd-Katz S; Sindiri S; Rotkopf R; Dutton-Regester K; Johansson P; Pritchard AL; Waddell N; Hill VK; Lin JC; Hevroni Y; Rosenberg SA; Khan J; Ben-Dor S; Niv MY; Ulitsky I; Mann GJ; Scolyer RA; Hayward NK; Samuels Y
    Nat Genet; 2015 Dec; 47(12):1408-10. PubMed ID: 26502337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma.
    Guhan SM; Shaughnessy M; Rajadurai A; Taylor M; Kumar R; Ji Z; Rashid S; Flaherty K; Tsao H
    J Invest Dermatol; 2021 Aug; 141(8):2018-2027.e4. PubMed ID: 33745909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.
    Whittaker SR; Theurillat JP; Van Allen E; Wagle N; Hsiao J; Cowley GS; Schadendorf D; Root DE; Garraway LA
    Cancer Discov; 2013 Mar; 3(3):350-62. PubMed ID: 23288408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
    Rajkumar S; Berry D; Heney KA; Strong C; Ramsay L; Lajoie M; Alkallas R; Nguyen TT; Thomson C; Ahanfeshar-Adams M; Dankner M; Petrella T; Rose AAN; Siegel PM; Watson IR
    Cell Rep; 2022 Apr; 39(1):110634. PubMed ID: 35385748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RASopathy Gene Mutations in Melanoma.
    Halaban R; Krauthammer M
    J Invest Dermatol; 2016 Sep; 136(9):1755-1759. PubMed ID: 27236105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated molecular drivers coordinate biological and clinical states in melanoma.
    Conway JR; Dietlein F; Taylor-Weiner A; AlDubayan S; Vokes N; Keenan T; Reardon B; He MX; Margolis CA; Weirather JL; Haq R; Schilling B; Stephen Hodi F; Schadendorf D; Liu D; Van Allen EM
    Nat Genet; 2020 Dec; 52(12):1373-1383. PubMed ID: 33230298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.